Erasca–BMS Tests Unproven Pan-RAS Plus PRMT5 Combo in MTAP-Deleted PDAC
Erasca, Inc. announced a clinical trial collaboration and supply agreement (CTCSA) with Bristol Myers Squibb (BMS) to evaluate Erasca’s pan-RAS molecular glue,...
TroFuse-015 OS Win Without PFS Leaves TROP2 Filing Strength Unproven
Merck announced that its pivotal Phase 3 TroFuse-015 trial, evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug...
AlpE Matches HRZE at 14 Days but Lacks Durable Cure Precedent graded for evidence
Swiss biopharmaceutical company BioVersys announced positive results from its 14-day Phase IIa ENABLE trial (NCT06748937) evaluating the antibiotic combination...
Regeneron Pushes Bispecifics Into MZL and AL Amyloidosis Without Pivotal Numbers
Regeneron Pharmaceuticals announced new and updated data from its hematology portfolio and pipeline will be presented across 14 abstracts at the American...
AR1001 Monotherapy Slows Decline but Overall Phase 3 Miss Clouds Approval Path
AriBio's once-daily oral drug, AR1001, a phosphodiesterase-5 (PDE5) inhibitor, demonstrated a significant 31% slowing of clinical decline in patients with...
GPS Phase 3 Survival Signal Faces Small Sample and No Clean Precedent Test
Sellas Life Sciences' investigational cancer vaccine, galinpepimut-S (GPS), demonstrated a statistically significant 41% reduction in the risk of death in a...
CagriSema Early Response Impresses but Post Hoc Data Cannot Carry Payer Approval
Novo Nordisk announced positive post hoc findings from its Phase III REDEFINE 1 trial, evaluating the investigational combination therapy CagriSema in 3,417...
WVE-007 Fat-Selective Signal Faces Phase 2a Liver and Payer Proof Test
Wave Life Sciences highlighted the progress of WVE-007, an investigational GalNac-siRNA targeting INHBE mRNA, at ObesityWeek® 2026. Phase 1 INLIGHT data...
Avexitide Phase 3 Cuts Severe Hypoglycemia but Faces First-in-Class Loneliness
Amylyx Pharmaceuticals has reported positive data from its Phase III LUCIDITY trial for avexitide, an investigational glucagon-like peptide-1 (GLP-1) receptor...
Randomized 68% Recurrence Cut Faces Durability and No-Treatment Comparator Scrutiny
CG Oncology announced positive Phase III results for its gene therapy, cretostimogene grenadenorepvec, in the PIVOT-006 trial for intermediate-risk and...
Vyvgart Hytrulo Sjögren's Futility Erases $1.4B Bet, Spares gMG and CIDP Core
Argenx has decided to discontinue the development of Vyvgart Hytrulo for Sjögren’s disease following an interim review of the Phase 3 UNITY study. An...
Tirzepatide RV Signal Intriguing but Far From Heart Failure Claim graded for evidence
At AHA 2026, tirzepatide showed promise for obesity-related heart failure with preserved ejection fraction (HFpEF) in a sub-study of the larger SUMMIT trial,...
Remibrutinib Sustains 52-Week CIndU Control But Quantitative Proof Still Withheld
Novartis announced 52-week results from the Phase III RemIND program for Rhapsido (remibrutinib) in chronic inducible urticaria (CIndU). The data demonstrated...
Ianalumab Week 108 Durability Impresses but Modest Separation and Open-Label Weight Limit Verdict
Novartis announced long-term results from the ongoing NEPTUNUS extension study of ianalumab in Sjögren’s disease, presented at the American College of...
Cellectis Buys Runway to 2028 But In Vivo Editing Remains Preclinical Promise
Cellectis announced its financial results for the third quarter ended September 30, 2026, alongside a comprehensive update on its activities, highlighting a...
Oyster $60M Degrader Bet Faces High Alzheimer's Bar Without Precedent
Venture capitalists are showing renewed interest in neuroscience drug research, with funding for central nervous system-focused startups gaining momentum....
Dual Joint-Weight Win Masks Single-Trial Limits and Dual-Cost Payer Hurdle
Eli Lilly and Company announced positive 52-week results from the Phase IIIb TOGETHER-PsA trial, evaluating Taltz (ixekizumab) combined with Zepbound...
HER3 Alpha Play Starts With Imaging While Efficacy and Precedent Are Absent
Actinium Pharmaceuticals has initiated patient enrolment in its Radiolabeled Antibody Distribution In Advanced Neoplasms with Zirconium-89 (RADIANZ) trial, an...
Afimetoran Phase II SRI-4 Strength Meets No Mechanistic Precedent and Phase III Proof Gap
Beeline Medicines has unveiled detailed Phase II data for its Bristol Myers Squibb (BMS)-licensed drug, afimetoran, in systemic lupus erythematosus (SLE). The...
HOPE-3 Meets Upper-Limb Primary but Cardiac Claim Lacks Numbers Ahead of BLA
Capricor Therapeutics announced that cardiac results from its HOPE-3 Phase 3 trial of Deramiocel in Duchenne muscular dystrophy (DMD) received the Outstanding...
MRD Enrichment Is Credible, Clearance Alone Will Not Carry Approval
Natera, Inc. has announced a clinical collaboration agreement with Incyte for a new Phase II study in colorectal cancer (CRC). This interventional trial will...
Zura Bio Abandons Hidradenitis After Placebo Tie as Cash Funds Sclerosis Pivot
Zura Bio has discontinued the clinical development of tibulizumab (ZB-106) in hidradenitis suppurativa (HS) following its failure to meet primary and secondary...
PepGen 46.5% Splicing Signal Outruns Proof in Crowded DM1 Race graded for evidence
PepGen Inc. announced positive topline results from the 10 mg/kg multiple ascending dose cohort of its Phase 2 FREEDOM2-DM1 trial (NCT06667453) for PGN-EDODM1...
Dual HBsAg Knockdown Hits 44% in Phase 3 But Faces Precedent Void graded for evidence
Vir Biotechnology's experimental two-drug combination, elebsiran and tobevibart, successfully met its primary objective in the first of three Phase 3 trials...
ALKIVIA Hits at 52 Weeks but Payer Walls and Thin Disclosure Cloud IMNM Bet
argenx announced positive Phase 3 ALKIVIA study data for VYVGART Hytrulo (efgartigimod) in autoimmune myositis, presented at ACR Convergence 2026. The study...
NATALEE Six-Year Survival Deepens but Payer and Maturity Hurdles Persist
Novartis announced six-year follow-up results from the Phase III NATALEE trial, demonstrating positive and clinically meaningful overall survival (OS) data for...
MINDSET Failure Closes 5-HT6 Adjunct Case After Large Precise Null Result
The article details how Vivek Ramaswamy's biotech background, particularly the failure of Axovant Sciences' Alzheimer's drug intepirdine, became a political...
Lean MASH Signal Intriguing but Post Hoc Markers Cannot Carry Label Expansion
Novo Nordisk announced results from a post hoc analysis of the phase 3 ESSENCE trial, revealing that once-weekly semaglutide 2.4 mg improved liver-related...
Survodutide Clears CV Safety Bar but Weight and Tolerability Cap Obesity Ambition
Zealand and Boehringer Ingelheim's weight loss drug, survodutide, demonstrated non-inferiority to placebo regarding cardiovascular safety in the Phase 3...
Paediatric Gradient Holds at 56 Weeks but Payer and Functional Proof Still Missing
Bristol Myers Squibb (BMS) announced longer-term 56-week data from its Phase III SCOUT-HCM trial evaluating Camzyos (mavacamten) in paediatric patients aged 12...
Allergan HA Signals in GLP-1 Faces Impress but Lack Controls for Expansion
Allergan Aesthetics, an AbbVie company, announced positive results from two Phase 4 studies, HARMONY IN DIVERSITY and HALO, evaluating aesthetic treatments in...
PIKTOR 33% Response Masks Single-Arm Paclitaxel Confound and No OS Precedent
Faeth Therapeutics' PIKTOR, a combination of serabelisib and sapanisertib, alongside paclitaxel, demonstrated positive outcomes in a single-arm Phase II trial...
MB-388 Enters Clinic Behind AC484 With No Efficacy Precedent to Anchor
Mondego Bio has initiated a first-in-human Phase Ia clinical trial for MB-388, an oral dual protein tyrosine phosphatase non-receptor type (PTPN2/PTPN1)...
Seladelpar Expands Toward Normalization but Payer Proof Still Hinges on Hard Outcomes
Gilead Sciences announced positive detailed results from its Phase 3 IDEAL study, demonstrating that Livdelzi (seladelpar) significantly improved alkaline...
Twice-Yearly Lenacapavir Wins Persistence But Pricing Blocks Prevention Scale
Gilead Sciences announced positive results from the Phase 2 PURPOSE 5 trial, demonstrating significantly higher one-year persistence for twice-yearly...
PRMT5 plus pan-RAS combo enters clinic with no data against proven RAS survival bar
Tango Therapeutics and Erasca have announced the initiation of a Phase 1/2 open-label, multicenter study for their oral PRMT5 inhibitor, vopimetostat, in...
Once-Monthly Maintenance Claim Leads Data With No Verifiable Differentiation Yet
Gan & Lee has announced Phase IIIb results for its once-monthly obesity treatment, claiming to be the first to deliver such data in the maintenance setting....
20 of 20 MRD Negative but Single-Arm Data Cannot Carry Frontline Approval
Johnson & Johnson is advancing its trispecific antibody, ramantamig, for multiple myeloma, with promising early mid-stage trial data to be presented at the...
Oral Wegovy Scales as CagriSema Chases Tirzepatide and Payers Balk
Novo Nordisk has raised its full-year 2026 financial outlook for adjusted sales and operating profit, driven by robust performance in its GLP-1 product...
CagriSema Superiority Claim Meets Payer Walls as Oral GLP-1s Fund Growth
Novo Nordisk has raised its full-year outlook for adjusted sales and operating profit for 2026, following a strong third quarter. Q3 2026 saw adjusted sales...
Merck Tests First Dual PDE3/4 Exacerbation Claim With No Clean Precedent
Merck has initiated ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial, to evaluate OHTUVAYRE (ensifentrine) for preventing chronic obstructive...
Dazodalibep Dual-Domain Win Meets First-in-Disease Payer and Safety Test
Amgen announced new data presentations at ACR Convergence 2026, highlighting its portfolio in rare and autoimmune diseases. Key findings from the Phase 3...
Second TYK2 Posts Deep Week-16 Clearance But Faces Payer Least-Cost Trap
InventisBio's tyrosine kinase 2 (TYK2) inhibitor, nomelcitinib, has achieved positive results in a pivotal China-based Phase III study (NCT07130604) for...
Cephea Pivotal Bets on Replacement Where Repair Fails Without Randomized Proof
Abbott has initiated the CROWN-MV pivotal trial to evaluate the safety and effectiveness of its investigational Cephea™ Mitral Valve System. This system is...
Amulet 360 Seals Better But Single-Arm Data Limits Approval Leverage
Abbott announced one-year results from its VERITAS study for the investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device...
Elranatamab Phase 3 PFS Win Upgrades Evidence But Payer Bar Remains Unmet
Pfizer announced positive topline results from the Phase 3 MagnetisMM-32 study, demonstrating that ELREXFIO (elranatamab) monotherapy met its primary endpoint...
Partial Hold Freezes Pediatric DEE Trial as Serotonergic Rivals Advance Without Clearance Path
The US Food and Drug Administration (FDA) has placed a partial clinical hold on Bright Minds Biosciences’ planned Phase II seizure trial for BMB-101, targeting...
Elranatamab Phase 3 PFS Win Faces OS Proof and Payer Price Squeeze
Pfizer Inc. announced positive topline results from the Phase 3 MagnetisMM-32 study, demonstrating that ELREXFIO (elranatamab) monotherapy met its primary...
Vykat Defends $107M Franchise as Eight Deaths Cloud Approved Benefit-Risk
Neurocrine Biosciences is defending its Prader-Willi syndrome therapy, Vykat, following another patient death, bringing the total reported deaths to eight. The...
Trial Initiation / First Patient In (FPI)Oncology · MTAP-deleted pancreatic ductal adenocarcinoma
21 Nov 2026
ClaimErasca announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate ERAS-0015 in combination with navlimetostat for MTAP-deleted pancreatic ductal adenocarcinoma.
Weak-Early
Rationale only, no combination data Planned Phase 1/2 with no efficacy or safety stated; supporting signals are daraxonrasib Phase 3 monotherapy and a single-patient BMS-986504 response in NSCLC.
Topline Results PositiveOncology · Locally advanced unresectable or metastatic gastroesophageal adenocarcinoma (third-line or later)
21 Nov 2026
ClaimMerck's investigational TROP2-directed ADC, sacituzumab tirumotecan, met its primary endpoint of overall survival in the Phase 3 TroFuse-015 trial for third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma.
Mixed
OS positive, magnitude unproven Global Phase 3 OS met versus TPC but PFS missed, ORR only nominal, with no HRs, medians or safety rates disclosed.
ClaimBioVersys' antibiotic combination, AlpE, demonstrated bacteria-killing benefits and an acceptable safety profile in a Phase IIa study for newly diagnosed, drug-sensitive pulmonary tuberculosis.
Weak-Early
14-day signal, no cure data ENABLE Phase IIa 14-day EBA with numerically similar activity to HRZE and acceptable safety, without mortality, treatment success, relapse or resistance data.
Topline Results PositiveHematology · Relapsed or refractory marginal zone lymphoma (MZL)
20 Nov 2026
ClaimRegeneron will present new and updated data from its hematology portfolio, including potentially pivotal data for odronextamab in relapsed/refractory marginal zone lymphoma, at the American Society of Hematology (ASH) 2026 Annual Meeting.
Mixed
Class validated, MZL unproven CD20xCD3 activity proven in DLBCL/FL and ELM-1/ELM-2 approval, but no MZL ORR/CR/PFS or safety figures stated for ASH 2026.
Topline Results PositiveNeuroscience · early Alzheimer’s disease
18 Nov 2026
ClaimAriBio's once-daily oral drug, AR1001, demonstrated a 31% slowing of clinical decline in patients with early Alzheimer’s receiving it as monotherapy in the Phase III POLARIS-AD study.
Mixed
Subgroup win, overall miss Phase 3 POLARIS-AD met CDR-SB primary in monotherapy with 31% slowing but missed overall significance, with no CIs or biomarker confirmation disclosed.
ClaimSellas Life Sciences' galinpepimut-S (GPS) cancer vaccine reduced the risk of death by 41% and prolonged median overall survival to 24 months compared to 14.7 months in a Phase 3 trial for acute myeloid leukemia.
Mixed
Randomized OS signal, small open-label dataset Phase 3 REGAL RCT reports 24 vs 14.7 months median OS and 41% risk reduction in 126 patients, but without CIs, p-values, safety or comparator detail and with ACTIVE_NOT_RECRUITING status.
Topline Results PositiveEndocrinology & Metabolic Diseases · obesity or overweight and comorbidities
17 Nov 2026
ClaimNovo Nordisk's investigational combination therapy CagriSema demonstrated positive post hoc findings from the Phase III REDEFINE 1 trial, showing significant weight reduction and improved physical function in adults with overweight or obesity.
Mixed
Predictive signal, not pivotal proof Phase 3 REDEFINE 1 post hoc responder split (25.4% vs 17.8%) and 73.1% function signal lack primary arm-level contrasts and durability beyond 68 weeks.
ClaimWave Life Sciences presented new data for WVE-007 at ObesityWeek® 2026, demonstrating its potential to improve body composition by inducing fat loss without muscle loss and supporting a once- or twice-yearly dosing regimen.
Weak-Early
Phase 1 signal only, pivotal proof pending INLIGHT is Phase 1 tier with up to 88% Activin E reduction and uncontrolled fat-loss signal; no Phase 2a weight, liver fat or morbidity data until 2027.
ClaimAmylyx Pharmaceuticals' investigational drug avexitide significantly reduced hypoglycaemic events in adult patients with post-bariatric hypoglycaemia in its Phase III LUCIDITY trial.
Mixed
Pivotal signal, no precedent anchor 78-patient 16-week Phase 3 RCT met composite and Level 2/Level 3 endpoints, but first-in-class status with small short prior base and undisclosed safety limits confidence.
Topline Results PositiveOncology · Non-muscle invasive bladder cancer (NMIBC)
17 Nov 2026
ClaimCG Oncology's cretostimogene grenadenorepvec significantly reduced the risk of recurrence by 68% in a Phase III trial for intermediate-risk and high-grade Ta non-muscle invasive bladder cancer.
Mixed
Randomized benefit, durability unproven PIVOT-006 Phase 3 RCT HR 0.32 at 17 months with no Grade ≥3 events, but no absolute rates, duration, progression or cystectomy data and no mechanistically matched precedent.
ClaimArgenx discontinued the development of Vyvgart Hytrulo for Sjögren’s disease after an interim review of the Phase 3 UNITY study indicated it would not meet its primary endpoint.
Contradicts
Phase 3 futility outweighs Phase 2 signal UNITY interim futility on systemic disease outweighs small RHO Phase 2 CRESS signal in 31 patients without formal testing.
ClaimTirzepatide demonstrated reductions in right ventricular mass and end-diastolic volume in patients with obesity-related heart failure with preserved ejection fraction in a sub-study of the SUMMIT trial.
Weak-Early
94-patient biomarker signal, no outcomes Randomized 94-patient SUMMIT sub-study reports RV mass and volume reductions without magnitude, p-values or clinical outcomes, below Phase 3 RCT weight.
ClaimNovartis' Rhapsido (remibrutinib) demonstrated sustained efficacy and a consistent safety profile through 52 weeks in patients with chronic inducible urticaria across three prevalent subtypes in the Phase III RemIND program.
Mixed
Sustained claim without numbers 52-week RemIND maintenance and placebo-switch catch-up claimed across SD, ColdU, CholU with consistent safety, but no absolute efficacy, threshold rates or safety tables disclosed.
ClaimNovartis' ianalumab demonstrated sustained and deepening reductions in systemic disease activity and improved patient outcomes over two years in the NEPTUNUS extension study for Sjögren’s disease, with a consistent safety profile.
Mixed
Durable ESSDAI signal, uncontrolled extension weight Phase 2b dose-response met primary plus Week 108 deepening to 65.1% low activity, but 300 mg placebo-adjusted -1.92 points was modest and extension is open-label through Week 204.
Trial Initiation / First Patient In (FPI)Endocrinology & Metabolic Diseases · Severe hypertriglyceridemia
14 Nov 2026
ClaimCellectis reported its Q3 2026 financial results and provided updates on its in vivo gene editing pipeline, including promising preclinical data for .HEAL-101 and .HEAL-201, with Phase 1 trials anticipated in China.
Weak-Early
Preclinical claim, no human proof Only preclinical efficacy and specificity with no targets, numbers or delivery; Phase 1 data not until late 2027 and early 2028.
ClaimVenture capitalists are demonstrating renewed interest in neuroscience drug development, exemplified by Oyster Therapeutics' recent $60 million Series A funding to target Alzheimer's disease.
Weak-Early
Financing only, no human data No target, dose, trial, endpoint or safety stated for Oyster; closest degrader peer is preclinical tier versus Phase 3 RCT bar.
ClaimEli Lilly and Company reported positive 52-week results from the Phase IIIb TOGETHER-PsA trial, demonstrating superior efficacy of Taltz combined with Zepbound over Taltz alone for active psoriatic arthritis in adults with overweight or obesity.
Mixed
Strong composite signal, single-trial limits Phase IIIb randomised n=271 shows 39.2% versus 1.7% on ACR50 plus 10% weight loss at week 36, but lifestyle background and no combo HTA leave payer case contingent.
Trial Initiation / First Patient In (FPI)Oncology · Advanced solid tumours
13 Nov 2026
ClaimActinium Pharmaceuticals has initiated patient enrolment in its RADIANZ imaging trial to support the pan-cancer therapeutic development of its HER3-targeting antibody radioconjugate, ATNM-400, in advanced solid tumours.
Weak-Early
Uptake signal, no therapeutic proof RADIANZ is imaging plus initial Phase 1 uptake without dose-limiting toxicities; no response, progression-free or overall survival for ATNM-400.
ClaimBeeline Medicines' afimetoran demonstrated statistically significant clinical benefit across all three doses in a Phase II systemic lupus erythematosus trial, meeting its primary endpoint.
Mixed
Strong Phase II signal, pivotal proof pending Randomized Phase II SRI-4 separation of 30.2 to 31.5 points at week 48 with consistent secondaries, but no Phase 3, BICLA or detailed safety yet.
ClaimCardiac results from Capricor's HOPE-3 Phase 3 trial of Deramiocel in Duchenne muscular dystrophy received the American Heart Association's Outstanding Research Award in Pediatric Cardiology.
Mixed
Phase 3 primary met, cardiac magnitude unproven HOPE-3 Phase 3 RCT (n=106) met PUL2.0 at p=0.029 but lower CI 0.47% is modest and LVEF/LGE lack numbers, with durability beyond 12 months unshown.
Trial Initiation / First Patient In (FPI)Oncology · colorectal cancer
12 Nov 2026
ClaimNatera has entered a clinical collaboration with Incyte for a Phase II study evaluating INCA33890 in colorectal cancer patients, utilizing Signatera as a primary and secondary endpoint to guide treatment for MRD-positive individuals.
Weak-Early
Enrichment plausible, approval unproven Phase II MRD-positive design has no results and ctDNA clearance is not validated to predict DFS/OS, with ALTAIR and DYNAMIC-III escalation failures as caution.
ClaimZura Bio has discontinued the clinical development of tibulizumab in hidradenitis suppurativa after it failed to meet primary and secondary endpoints in the Phase II TibuSHIELD study.
Mixed
Controlled failure ends HS, future unproven Randomized Phase 2 TibuSHIELD in 247 patients missed AN-count and HiSCR50/75 endpoints with near-identical active-placebo rates, but SSc and PMR programs have no disclosed efficacy data.
ClaimPepGen's PGN-EDODM1 demonstrated positive topline results in the 10 mg/kg cohort of the Phase 2 FREEDOM2-DM1 trial, showing significant splicing correction and functional improvements in patients with myotonic dystrophy type 1.
Weak-Early
Early signal, no pivotal weight Randomized Phase 2 cohort with 46.5% splicing correction and vHOT/grip directionality but 24 patients estimated, no p-values or durability, below Phase 3 peers.
Topline Results PositiveInfectious Diseases & Vaccines · Chronic hepatitis D
10 Nov 2026
ClaimVir Biotechnology's experimental two-drug combination, elebsiran and tobevibart, met its primary and a key secondary endpoint in the first of three Phase 3 trials for chronic hepatitis D.
Mixed
Phase 3 signal but incomplete package First Phase 3 met 44% vs none at 48 weeks, but two trials unread, no durability or safety detail, and no matched precedent.
Claimargenx announced positive Phase 3 ALKIVIA study data for efgartigimod in autoimmune myositis, meeting its primary endpoint and demonstrating clinically meaningful benefits, particularly in immune-mediated necrotizing myopathy (IMNM).
Mixed
Pivotal win, payer and granularity gaps Phase 3 ALKIVIA met mean TIS at Week 52 in combined and IMNM populations, but without responder distributions, background therapy or quantified safety and with negative gMG HTA precedents.
Topline Results PositiveOncology · HR+/HER2- early breast cancer at high risk of recurrence
10 Nov 2026
ClaimNovartis's Kisqali, combined with endocrine therapy, significantly reduced the risk of death by nearly 20% in patients with HR+/HER2- early breast cancer at high risk of recurrence over six years in the Phase III NATALEE trial.
Mixed
Durable signal, immature proof Phase 3 RCT NATALEE shows deepening iDFS to 5.3% and OS HR=0.809, but without CIs, p-values, or censoring resolution versus monarchE success.
ClaimVivek Ramaswamy's biotech career, particularly the failure of Axovant's Alzheimer's drug intepirdine in a pivotal Phase 3 trial, became a significant point of scrutiny during his political campaigns.
Strong
Definitive dual-primary Phase 3 failure 1315-patient MINDSET missed ADAS-Cog and ADCS-ADL co-primaries with tight null intervals, replicating three idalopirdine Phase 3 RCTs.
ClaimA post hoc analysis of the phase 3 ESSENCE trial found that once-weekly semaglutide 2.4 mg improved liver-related measures in adults with MASH and liver scarring with a BMI below 27 kg/m² at week 72.
Weak-Early
Post hoc markers without histology 106-patient post hoc BMI below 27 analysis reports only liver enzymes and non-invasive markers at week 72 versus placebo, below ESSENCE dual histology standard that supported approval.
ClaimBristol Myers Squibb reported longer-term 56-week data from its Phase III SCOUT-HCM trial, demonstrating continued efficacy and a favorable safety profile for Camzyos (mavacamten) in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy.
Mixed
Durable gradient, unproven functional benefit 56-week 48.1mmHg Valsalva reduction with no LVEF below 50% in SCOUT-HCM Phase 3, but n=40-44 and no quantified NYHA, pVO2, KCCQ or SRT outcomes.
Topline Results PositiveOthers · Aesthetic improvement for facial changes due to GLP-1 medication use
10 Nov 2026
ClaimAllergan Aesthetics' Phase 4 HARMONY IN DIVERSITY and HALO studies demonstrated statistically significant improvements in patient satisfaction with facial appearance following aesthetic treatments in adults on GLP-1 medications.
Weak-Early
Large scores, tiny uncontrolled datasets 42.4-point and 39.6-point FACE-Q gains rest on n=30 and n=25 interim single-arm Phase 4 data with no comparator and confounded triple therapy.
Topline Results PositiveOncology · Advanced or recurrent endometrial cancer
10 Nov 2026
ClaimFaeth Therapeutics' PIKTOR combination demonstrated improved outcomes in a Phase II trial for patients with advanced or recurrent endometrial cancer who had progressed on prior treatments.
Weak-Early
Small uncontrolled signal, no survival proof Single-arm Phase 2 n=42, 36 evaluable, 33% ORR and 7.4-month PFS with paclitaxel confound, no OS or comparator versus Phase 3 RCT standard.
Trial Initiation / First Patient In (FPI)Oncology · Advanced solid tumours
07 Nov 2026
ClaimMondego Bio has initiated a first-in-human Phase Ia clinical trial for MB-388, an oral dual PTPN2/PTPN1 inhibitor designed to overcome resistance to cancer immunotherapy.
Weak-Early
First human dose, zero patient efficacy Phase Ia SAD/MAD in healthy volunteers only, with PK/PD due December 2026 and no ORR, PFS, OS or patient safety to support efficacy conclusions.
ClaimThe Phase 3 IDEAL study showed that Livdelzi (seladelpar) significantly increased alkaline phosphatase (ALP) normalization rates in adults with primary biliary cholangitis (PBC) compared to placebo.
Mixed
Strong surrogate, unproven hard outcomes Phase 3 RCT replication on ALP and pruritus supports use, but no head-to-head, no survival benefit, and conditional approval pending AFFIRM constrain confidence.
Topline Results PositiveInfectious Diseases & Vaccines · HIV prevention
07 Nov 2026
ClaimTwice-yearly injectable lenacapavir demonstrated significantly higher one-year persistence for HIV pre-exposure prophylaxis compared to daily oral emtricitabine/tenofovir disoproxil fumarate in the PURPOSE 5 trial.
Mixed
Persistence strong, pivotal weight elsewhere PURPOSE 5 is randomized Phase 2 persistence 85.6% vs 46.3% with zero acquisitions, supportive to Phase 3 PURPOSE 1/2 efficacy but lacking safety and comparator incidence detail.
Trial Initiation / First Patient In (FPI)Oncology · MTAP-deleted pancreatic ductal adenocarcinoma
06 Nov 2026
ClaimTango Therapeutics and Erasca have initiated a Phase 1/2 study evaluating the oral PRMT5 inhibitor vopimetostat in combination with the pan-RAS molecular glue ERAS-0015 for patients with MTAP-deleted pancreatic ductal adenocarcinoma and MTAP-deleted/RAS-mutant non-small cell lung cancer.
Weak-Early
Rationale only, no combination data Phase 1/2 MTD objective only with no efficacy, safety or PK results; nearest peers are preclinical or mechanistically distinct and cannot carry pivotal weight.
ClaimGan & Lee claims to be the first to deliver Phase IIIb results looking at a once-monthly obesity treatment in the maintenance setting.
Weak-Early
Claim outpaces disclosed evidence No mechanism, comparator, efficacy or safety figures for the Phase IIIb maintenance asset; no matching trial record to weight as pivotal data.
ClaimEarly data for Johnson & Johnson's trispecific antibody, ramantamig, demonstrated minimal residual disease negativity in all evaluable newly diagnosed multiple myeloma patients in a mid-stage trial.
Weak-Early
20-patient MRD signal, no pivotal weight All 20 evaluable patients MRD-negative after three cycles in single-arm early data, without PFS, OS, safety or comparator versus Phase 3 RCT standards.
ClaimNovo Nordisk raised its full-year 2026 financial outlook due to strong Q3 GLP-1 product sales, particularly from its obesity portfolio.
Mixed
Pivotal wins, payer and durability caps SELECT Phase 3 RCT met 3P-MACE HR 0.80 and CagriSema Phase 3 met glycemic endpoints, but ICER $185,646, 16.6% discontinuation and single-arm switch data limit breadth.
ClaimNovo Nordisk has raised its full-year financial outlook for 2026, driven by robust Q3 GLP-1 product sales, particularly Wegovy and Ozempic, and positive late-stage pipeline advancements for CagriSema and Frehemgo.
Mixed
Headline efficacy outpaces disclosed evidence 21% loss and superiority vs tirzepatide lack design, significance, safety and durability; Phase 3 RCT weight cannot be assumed without data.
Trial Initiation / First Patient In (FPI)Respiratory · Chronic Obstructive Pulmonary Disease exacerbations
05 Nov 2026
ClaimMerck has initiated the Phase 3 ENHANCE-3 clinical trial to evaluate OHTUVAYRE (ensifentrine) for the prevention of COPD exacerbations in adult patients receiving standard of care.
Mixed
Plausible mechanism, exacerbation benefit unproven ENHANCE-3 (NCT07874815) tests annualized exacerbation rate in 2,136 patients but is NOT_YET_RECRUITING with no results; prior 24-week lung-function trials excluded dual/triple backgrounds.
ClaimAmgen's Phase 3 OASIZ-301 study of dazodalibep demonstrated statistically significant and clinically meaningful reductions in systemic disease activity and patient-reported dryness in Sjögren's disease.
Mixed
Phase 3 replicates Phase 2, safety pending OASIZ-301 ESSDAI and ESSPRI/DASPRI significance replicates randomized Phase 2 NCT04129164, but full safety, durability and HTA precedent remain absent.
ClaimInventisBio's TYK2 inhibitor nomelcitinib met its primary endpoint in a China-based Phase III study for moderate-to-severe plaque psoriasis, demonstrating significant improvement in disease severity and a favorable safety profile.
Mixed
Deep clearance on thin single-region data NCT07130604 Phase 3 RCT met week-16 PASI 90-level and PGA endpoints in 391 patients versus placebo, but without active-comparator, durability or detailed safety to match POETYK precedent.
Trial Initiation / First Patient In (FPI)Cardiovascular · Symptomatic mitral valve disease
04 Nov 2026
ClaimAbbott has initiated the CROWN-MV pivotal trial to evaluate the safety and effectiveness of its investigational Cephea Mitral Valve System for symptomatic mitral valve disease in patients not suitable for surgery or transcatheter repair.
Weak-Early
Pivotal intent without pivotal data CROWN-MV targets up to 585 patients but discloses no Cephea efficacy or safety figures; all TMVR support is single-arm tier, not Phase 3 RCT.
Topline Results PositiveCardiovascular · Severe Coronary Calcification
04 Nov 2026
ClaimAbbott's investigational SonicForce™ Coronary IVL System met its primary safety and effectiveness endpoints in the TECTONIC CAD IVL IDE Study, demonstrating excellent early clinical outcomes in patients with severe coronary calcification.
Mixed
Strong early signal, no durability 335-patient multicenter IDE met 30-day endpoints at 97% success and 0.3% TLF but lacks PG thresholds, OCT mechanism and 1-year MACE/TLF.
ClaimAbbott's investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder demonstrated high rates of LAA closure and a low incidence of stroke in non-valvular atrial fibrillation patients at one year in the VERITAS study.
Mixed
Strong seal, uncontrolled stroke claim VERITAS single-arm closure and stroke-free rates lack randomized comparator and retrieved one-year safety, below Amulet IDE Phase 3 RCT weight.
Topline Results PositiveOncology · Relapsed or Refractory Multiple Myeloma
04 Nov 2026
ClaimPfizer's ELREXFIO demonstrated a statistically significant and clinically meaningful reduction in the risk of disease progression or death in adults with relapsed or refractory multiple myeloma in the Phase 3 MagnetisMM-32 study.
Mixed
Randomized PFS win, survival immature MagnetisMM-32 met PFS with 68% at 18 months upgrading single-arm tier, but OS, hazard ratio and detailed safety remain undisclosed.
Trial Halted / TerminatedNeuroscience · Developmental and epileptic encephalopathies (DEEs)
04 Nov 2026
ClaimThe FDA has placed a partial clinical hold on Bright Minds Biosciences' planned Phase II seizure trial for BMB-101 due to toxicity findings in mice and insufficient pharmacokinetic and juvenile toxicity data.
Weak-Early
Paused pre-Phase II, no efficacy data Planned Phase II under partial hold with no BMB-101 responder, dose or retention data; only class-level fenfluramine RCT and RWE plus preliminary bexicaserin and EPX-100 datasets exist.
Topline Results PositiveHematology · Relapsed or Refractory Multiple Myeloma
04 Nov 2026
ClaimPfizer's ELREXFIO demonstrated a statistically significant and clinically meaningful progression-free survival benefit as monotherapy in adults with relapsed or refractory multiple myeloma in the Phase 3 MagnetisMM-32 study.
Mixed
Randomized PFS win, OS unproven MagnetisMM-32 met PFS with median not reached and 68% at 18 months, but no hazard ratio, OS, or grade-specific safety disclosed.
Trial Initiation / First Patient In (FPI)Rare Diseases & Genetics · Prader-Willi syndrome
04 Nov 2026
ClaimNeurocrine Biosciences is defending the safety profile of its Prader-Willi syndrome drug, Vykat, following another patient death and plans a new study to address dosing and safety concerns in complex patients.
Mixed
Benefit shown, fatal risk unresolved Withdrawal superiority P=0.0022 and long-term HQ-CT -9.9 p<0.0001 support benefit, but DESTINY PWS missed overall primary P=.198 and eight post-marketing deaths exceed trial safety.